Verrica Pharmaceuticals Inc. VRCA
We take great care to ensure that the data presented and summarized in this overview for Verrica Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRCA
View all-
Armistice Capital, LLC New York, NY8.92MShares$70.9 Million1.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.25MShares$25.8 Million0.86% of portfolio
-
Boothbay Fund Management, LLC New York, NY2.59MShares$20.6 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$14.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.13MShares$8.98 Million0.0% of portfolio
-
State Street Corp Boston, MA523KShares$4.16 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA477KShares$3.79 Million0.0% of portfolio
-
Sovran Advisors, LLC San Diego, CA407KShares$3.24 Million0.04% of portfolio
-
Morgan Stanley New York, NY362KShares$2.88 Million0.0% of portfolio
-
Heights Capital Management, Inc San Francisco, CA351KShares$2.79 Million0.12% of portfolio
Latest Institutional Activity in VRCA
Top Purchases
Top Sells
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Insider Transactions at VRCA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 17
2025
|
Christopher G. Hayes CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,315
-2.39%
|
$0
$0.65 P/Share
|
|
Nov 26
2024
|
Paul B Manning |
SELL
Bona fide gift
|
Direct |
450,000
-1.71%
|
-
|
|
Nov 26
2024
|
John A Stalfort Iii |
BUY
Bona fide gift
|
Direct |
50,000
+2.6%
|
-
|
|
Nov 26
2024
|
Jayson Rieger CEO and President |
BUY
Bona fide gift
|
Direct |
50,000
+5.36%
|
-
|
|
Nov 22
2024
|
Paul B Manning |
BUY
Open market or private purchase
|
Indirect |
4,494,382
+42.92%
|
-
|
|
Nov 22
2024
|
Paul B Manning |
BUY
Open market or private purchase
|
Direct |
18,426,966
+41.22%
|
-
|
|
Nov 22
2024
|
John A Stalfort Iii |
BUY
Open market or private purchase
|
Direct |
1,123,595
+38.12%
|
-
|
|
Nov 22
2024
|
Jayson Rieger CEO and President |
BUY
Open market or private purchase
|
Direct |
280,898
+25.22%
|
-
|
|
Nov 06
2024
|
John J. Kirby Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
54,267
+50.0%
|
-
|
|
Sep 19
2024
|
Paul B Manning |
BUY
Bona fide gift
|
Indirect |
2,675,610
+50.0%
|
-
|
|
Sep 19
2024
|
Paul B Manning |
SELL
Bona fide gift
|
Indirect |
2,675,611
-100.0%
|
-
|
|
Aug 27
2024
|
Ted White PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
9,021
-4.01%
|
$18,042
$2.46 P/Share
|
|
Aug 27
2024
|
Terry Kohler CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
7,899
-15.02%
|
$15,798
$2.46 P/Share
|
|
Aug 27
2024
|
Joe Bonaccorso CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,993
-10.95%
|
$17,986
$2.46 P/Share
|
|
Aug 27
2024
|
Gary Goldenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,601
-3.68%
|
$7,202
$2.46 P/Share
|
|
Aug 27
2024
|
Christopher G. Hayes CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,530
-8.27%
|
$19,060
$2.46 P/Share
|
|
Aug 26
2024
|
Ted White PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
24,979
-9.99%
|
$49,958
$2.66 P/Share
|
|
Aug 26
2024
|
Terry Kohler CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
21,820
-29.32%
|
$43,640
$2.66 P/Share
|
|
Aug 26
2024
|
Joe Bonaccorso CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
24,709
-23.13%
|
$49,418
$2.66 P/Share
|
|
Aug 26
2024
|
Gary Goldenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,888
-9.18%
|
$19,776
$2.66 P/Share
|
Last 12 Months Summary
| Bona fide gift | 2.78M shares |
|---|---|
| Open market or private purchase | 24.3M shares |
| Grant, award, or other acquisition | 54.3K shares |
| Open market or private sale | 249K shares |
|---|---|
| Bona fide gift | 3.13M shares |